申请人:GlaxoSmithKline Intellectual Property Development
Limited
公开号:EP3541813A1
公开(公告)日:2019-09-25
[EN] ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF<br/>[FR] ISOXAZOLIDINES EN TANT QU'INHIBITEURS DE RIPK1 ET LEUR UTILISATION
申请人:[en]SANOFI
公开号:WO2023083847A1
公开(公告)日:2023-05-19
Isoxazolidines as RIPK1 inhibitors and use thereof The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.